229 patents
Page 6 of 12
Utility
Methods for high throughput receptor:ligand identification
18 Jan 22
Methods and systems for high-throughput Identification of receptor:ligand interactions are provided.
Steven C. Almo, Ronald D. Seidel, III, Brandan S. Hillerich, Sarah C. Garrett-Thomson, James D. Love
Filed: 25 Jul 18
Utility
MONOCLONAL ANTIBODIES AGAINST IgV DOMAIN OF B7-H3 AND USES THEREOF
13 Jan 22
The present disclosure provides monoclonal antibodies that bind to an IgV domain of human B7-H3.
Xingxing ZANG
Filed: 15 Nov 19
Utility
3qeznwh8rjlalv jsg93p5c0aksz6atf5mae19bekzhp92qt
4 Jan 22
Methods, pharmaceutical compositions and vaccines comprising an attenuated bacteria that expresses a recall antigen are disclosed for treatment of cancer.
Claudia Gravekamp
Filed: 26 Apr 16
Utility
t0t83xqsa9wg2mu7fa2vk7xv58gwf0fx57vz0hf4d7 1mtc
30 Dec 21
Methods and systems for obtaining inhibitors of human DNA methyltransferase 1 (DNMT1) are disclosed where the methods involve designing compounds that resemble the DNMT1 transition state.
Vern L. Schramm, Quan Du, Zhen Wang
Filed: 3 Sep 21
Utility
nhu0jwq9cbx18gfy0ex3he817yyxz9n8m
16 Dec 21
Provided are methods of treating an HHLA2-bearing tumor in a subject with a fusion protein comprising an IgV-like domain of a TMIGD2 sufficient to treat the HHLA2-bearing tumor.
Xingxing Zang, Jordan M. Chinai, Murali Janakiram, Steven C. Almo, Andras Fiser
Filed: 4 Jan 21
Utility
n3c4dr0v9a9unvq904 syqy4oo
16 Dec 21
Ana Maria Cuervo, Evripidis Gavathiotis
Filed: 10 Oct 19
Utility
elc0prd0apuvm2bu0xns0tgg7arr9e04asm
16 Dec 21
Adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP) is caused by dominant inactivating mutations in the colony stimulating factor receptor 1 (CSF1R) kinase domain.
Richard E. Stanley, Violeta Chitu
Filed: 13 Oct 19
Utility
3m476k3 yzci55mn8q6jx4azeqn3nzksr6obno1bdjbhagipgw5woiu2k
9 Dec 21
Provided are isolated antibodies and antigen-binding fragments thereof that specifically bind CEACAM1, including the IgV domain of CEACAM1, as well as pharmaceutical formulations, kits, and methods of use thereof.
Xingxing ZANG
Filed: 20 Dec 19
Utility
zgtbse3mme9oenzf064r60rlqla7xfups4hdys8
2 Dec 21
Methods of vaccinating, immunizing and/or treating a subject against a herpes simplex virus infection or a disease caused by a herpes simplex virus infection comprise administering to the subject an effective amount of a HSV-2 single-cycle virus and an effective amount of a recombinant HSV-2 glycoprotein D, wherein the HSV-2 single-cycle virus comprises HSV-2 having a deletion of glycoprotein D-encoding gene in the genome and the HSV-2 is phenotypically complemented with an HSV-1 glycoprotein D on a lipid bilayer of the HSV-2.
Betsy C. HEROLD, Clare Burn Aschner
Filed: 1 Jun 21
Utility
0vxz710bllbl5wx9snbslpmodurkwp2ne1q7oluqvjc3cpv
30 Nov 21
Vern L. Schramm, Shanzhi Wang, Antti Marko Haapalainen, Gary Brian Evans, Richard Hubert Furneaux, Keith Clinch, Peter Charles Tyler, Shivali Ashwin Gulab
Filed: 7 Aug 13
Utility
r7v310k7aex2e8ne07qavwlkscphxowo2765g1lk8fqgjz
25 Nov 21
Methods of preferentially enhancing in a subject an antibody-dependent cell-mediated cytotoxicity (ADCC) antibody response over a neutralizing antibody response to a vaccine for an infectious agent using herpesvirus entry mediator (HVEM) agonists, and related compositions.
Betsy HEROLD, Clare BURN
Filed: 17 Oct 19
Utility
6cehvuzwou504re ookte9serraoklm
18 Nov 21
Methods and compositions for reducing a ratio of collagen III to collagen I in wounded skin, treating wounds and accelerating healing is provided with a surfactant polymer dressing comprising FL2 siRNA, collagen and a poloxamer.
David James SHARP, Brian O'ROURKE, Adam Hildyard KRAMER
Filed: 23 Oct 19
Utility
4dk9xmdyao82c00iw hff6u6wyc8p5ps8h8m8rksyefol3aonrvw88i3f
18 Nov 21
Anti-CCHFV antibodies with neutralizing potency and protective efficacy against CCHFV are provided, as well as methods for their identification, isolation, generation, and methods for their preparation and use are provided.
Zachary A. Bornholdt, Akaash Mishra, Laura M. Walker, Noel T. Pauli, Daniel Maurer, Kartik Chandran, Jens Maximilian Fels, Dafna Abelson, Jason Scott McLellan, Jonathan R. Lai, Ariel Wirchnianski, Olivia Vergnolle
Filed: 5 May 21
Utility
t16l6vjqfhpxk1fao2nzu76r
18 Nov 21
Methods are disclosed for enhancing growth of a human acute myeloid leukemia (AML) sample, a human myelodysplastic syndrome (MDS) sample, a human IL-8 dependent tumor sample, human preleukemia cells, and a human preleukemia clone or subclone ex vivo or in a xenograft animal model comprising adding human interleukin-8 (hIL-8) or a hIL-8 agonist to the sample or administering hIL-8 or a hIL-8 agonist to the animal model or expressing a gene encoding hIL-8 or a hIL-8 agonist in the animal model.
Amit Verma, Ulrich Steidl, Britta Will, Tihomira Todorova
Filed: 23 Sep 19
Utility
8gkq8cy v80e8zllxxtz6
16 Nov 21
Synthetic fragment antigen-binding (Fab) antibodies are disclosed that bind to an N-terminal activation site of BCL-2-associated X-protein (BAX) and inhibit BAX activation.
Evripidis Gavathiotis, Jonathan R. Lai, Sachdev Sidhu
Filed: 10 Aug 20
Utility
dukoqby0qu4gju5kx4m6 t7us
9 Nov 21
Methods and products are provided for determining if a subject having a tumor is at risk of metastasis of the tumor.
John Condeelis, Tony Tsz-Cheong Ng, Gregory Weitsman
Filed: 24 Jul 18
Utility
ocjldfe73scy0bo3oxg7dfihaeopj4tz2hsn3lobnnonmezj1f10pg tox
4 Nov 21
Methods and compositions are provided for inhibiting or treating metastasis based on discoveries regarding Kif19 and Cep192.
David SHARP, Brian O'ROURKE
Filed: 15 Jul 21
Utility
wc6otpn4ufrxh6a35cxtrjzylqd8v4j8awwvqsj
28 Oct 21
The present disclosure provides a method of improvement, preservation, prophylaxis, or inhibition-of-deterioration of a healthspan parameter of a mammalian subject.
Pedro Beltran, Derek Huffman, Nir Brazilal, Pinchas Cohen
Filed: 30 Aug 18
Utility
hlhgd5hu608ezka6ogy6zvha
21 Oct 21
Microvesicles produced by stem cells grown on a silk scaffold for enhancing stem cell self-renewal/proliferation and promoting tenogenesis in damaged tendons, and their use in tendon wound repair and tendinopathy treatment.
Hui B. Sun
Filed: 21 Aug 17
Utility
ly7a0lqit4on f57zuivuqogahlh3k4w7qh5cafn6yd4
19 Oct 21
Disclosed are bispecific antibodies and bispecific fusion constructs that bind to Niemann-Pick C1 (NPC1) receptor for treating or preventing filovirus infections, pharmaceutical compositions comprising the bispecific antibodies, and therapeutic methods using the bispecific antibodies.
Kartik Chandran, Anna Z. Wec, Elisabeth K. Nyakatura, Jonathan R. Lai
Filed: 19 Jun 19